Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CRISTINA GASPARETTO

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1730242504
CMS profile
896465
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$123,330.83

57 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $64,259.68 27
Karyopharm Therapeutics Inc. $29,946.08 11
GENZYME CORPORATION $18,479.02 9
E.R. Squibb & Sons, L.L.C. $6,764.08 5
Merck Sharp & Dohme LLC $2,135.00 1
Janssen Biotech, Inc. $1,262.50 1
Celgene Corporation $425.01 2
PFIZER INC. $59.46 1

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CRISTINA GASPARETTO

NPI 1730242504 · CMS profile ID 896465

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730242504?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CRISTINA GASPARETTO, NPI 1730242504, CMS profile ID 896465. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730242504?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CRISTINA GASPARETTO, NPI 1730242504, CMS profile ID 896465. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730242504?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CRISTINA GASPARETTO, NPI 1730242504, CMS profile ID 896465, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1730242504?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

57 matching records · $123,330.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 57 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–57 of 57.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $4,800.0002/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944870953 CMS
GlaxoSmithKline, LLC. $1,348.7502/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944870919 CMS
GlaxoSmithKline, LLC. $103.3602/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944870949 CMS
GlaxoSmithKline, LLC. $1,600.0002/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944870941 CMS
Karyopharm Therapeutics Inc. $3,000.0001/29/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946514633 CMS
GENZYME CORPORATION $729.0001/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938844839 CMS
Karyopharm Therapeutics Inc. $3,000.0001/27/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946514641 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $44,394.10 38
PY2020 $84,698.43 49
PY2021 $125,306.70 64
PY2022 $123,330.83 57
PY2023 $72,187.59 30
PY2024 $83,621.18 40
PY2025 $79,192.06 45

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $228,859.62 67
PY2024 Principal investigator $367,241.34 37
PY2023 Recipient $3,630.00 3
PY2023 Principal investigator $79,316.12 31
PY2022 Recipient $2,550.00 5
PY2022 Principal investigator $153,285.82 31
PY2021 Recipient $5,400.00 9
PY2021 Principal investigator $331,843.71 44
PY2020 Recipient $2,102.30 5
PY2020 Principal investigator $890,075.86 70
PY2019 Recipient $81,069.66 9
PY2019 Principal investigator $579,983.10 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,100.00 12/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202535019
Principal investigator 1 ABBVIE INC. $1,349.12 12/04/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202526562
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,580.00 12/03/2025 Non-covered Recipient Entity
Duke University
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235997625
Principal investigator 1 Karyopharm Therapeutics Inc. $2,412.90 12/03/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663138
Principal investigator 1 Karyopharm Therapeutics Inc. $184.00 12/03/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663198
Principal investigator 1 Karyopharm Therapeutics Inc. $184.00 12/03/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663218
Principal investigator 1 Karyopharm Therapeutics Inc. $651.60 11/05/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663166
Principal investigator 1 Karyopharm Therapeutics Inc. $184.00 11/05/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663214
Principal investigator 1 ABBVIE INC. $956.80 11/04/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202520547
Principal investigator 1 ABBVIE INC. $5,420.16 10/09/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202513981
Principal investigator 1 Karyopharm Therapeutics Inc. $2,412.90 10/02/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663148
Principal investigator 1 Karyopharm Therapeutics Inc. $2,412.90 10/02/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663160
Principal investigator 1 Karyopharm Therapeutics Inc. $2,412.90 10/02/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663164
Principal investigator 1 Karyopharm Therapeutics Inc. $2,412.90 10/02/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663170
Principal investigator 1 Karyopharm Therapeutics Inc. $184.00 10/02/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663174
Principal investigator 1 Karyopharm Therapeutics Inc. $2,412.90 10/02/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663182
Principal investigator 1 Karyopharm Therapeutics Inc. $2,412.90 10/02/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663200
Principal investigator 1 Karyopharm Therapeutics Inc. $35.91 10/02/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663220
Principal investigator 1 Karyopharm Therapeutics Inc. $184.00 10/02/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663222
Principal investigator 1 Karyopharm Therapeutics Inc. $2,412.90 10/02/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663226
Principal investigator 1 ABBVIE INC. $1,095.68 09/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Study of Combination Therapy With Venetoclax Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202507853
Principal investigator 1 ABBVIE INC. $1,954.77 08/12/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202504221
Principal investigator 1 Karyopharm Therapeutics Inc. $155.70 08/06/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663158
Principal investigator 1 Karyopharm Therapeutics Inc. $155.70 08/06/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663190
Principal investigator 1 Karyopharm Therapeutics Inc. $155.70 08/06/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663192
Principal investigator 1 ABBVIE INC. $4,463.36 08/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202501936
Principal investigator 1 Karyopharm Therapeutics Inc. $1,522.80 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663130
Principal investigator 1 Karyopharm Therapeutics Inc. $1,522.80 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663132
Principal investigator 1 Karyopharm Therapeutics Inc. $2,362.50 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663136
Principal investigator 1 Karyopharm Therapeutics Inc. $5,092.20 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663144
Principal investigator 1 Karyopharm Therapeutics Inc. $5,092.20 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663146
Principal investigator 1 Karyopharm Therapeutics Inc. $932.40 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663152
Principal investigator 1 Karyopharm Therapeutics Inc. $2,003.40 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663154
Principal investigator 1 Karyopharm Therapeutics Inc. $3,069.00 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663162
Principal investigator 1 Karyopharm Therapeutics Inc. $1,210.50 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663172
Principal investigator 1 Karyopharm Therapeutics Inc. $2,464.20 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663178
Principal investigator 1 Karyopharm Therapeutics Inc. $2,412.90 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663180
Principal investigator 1 Karyopharm Therapeutics Inc. $1,034.10 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663184
Principal investigator 1 Karyopharm Therapeutics Inc. $1,385.10 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663186
Principal investigator 1 Karyopharm Therapeutics Inc. $1,385.10 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663188
Principal investigator 1 Karyopharm Therapeutics Inc. $932.40 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663194
Principal investigator 1 Karyopharm Therapeutics Inc. $1,522.80 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663204
Principal investigator 1 Karyopharm Therapeutics Inc. $5,092.20 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663206
Principal investigator 1 Karyopharm Therapeutics Inc. $3,069.00 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663210
Principal investigator 1 Karyopharm Therapeutics Inc. $1,210.50 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663216
Principal investigator 1 Karyopharm Therapeutics Inc. $2,412.90 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663224
Principal investigator 1 Karyopharm Therapeutics Inc. $3,069.00 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663228
Principal investigator 1 Karyopharm Therapeutics Inc. $2,464.20 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663230
Principal investigator 1 Karyopharm Therapeutics Inc. $1,210.50 08/04/2025 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma No dispute reported 06/30/2026 1246663232
Principal investigator 1 ABBVIE INC. $26,691.90 07/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202493777
Principal investigator 1 ABBVIE INC. $1,806.72 06/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202490615
Principal investigator 1 ABBVIE INC. $26,978.42 06/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202487867
Principal investigator 1 ABBVIE INC. $9,240.40 06/02/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202487321
Principal investigator 1 ABBVIE INC. $3,466.24 05/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202482071
Principal investigator 1 ABBVIE INC. $4,655.00 03/27/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
M20-258 - Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202466528
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,942.34 03/25/2025 Non-covered Recipient Entity
Duke Cancer Institute-Duke Univ. Medical Center
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235997647
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,648.18 03/25/2025 Covered Recipient Teaching Hospital
Duke University Hospital
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1236001292
Principal investigator 1 ABBVIE INC. $3,672.32 03/06/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
M15-538 - Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202456376
Principal investigator 1 ABBVIE INC. $24,910.10 03/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202455541
Principal investigator 1 ABBVIE INC. $1,251.00 02/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
M15-538 - Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202451225
Principal investigator 1 ABBVIE INC. $7,086.00 02/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
M15-538 - Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202451227
Principal investigator 1 ABBVIE INC. $2,011.52 02/05/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
M15-538 - Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202444866
Principal investigator 1 ABBVIE INC. $1,330.00 02/03/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202443633
Principal investigator 1 ABBVIE INC. $5,779.84 01/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
M15-538 - Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202438116
Principal investigator 1 ABBVIE INC. $2,698.24 01/13/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
M15-538 - Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) No dispute reported 06/30/2026 1202438120
Principal investigator 1 ABBVIE INC. $4,695.00 01/08/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
M20-258 - Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202437252
Principal investigator 1 Celgene Corporation $3,226.00 01/08/2025 Non-covered Recipient Entity
Duke Occupational & Envir Med
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1222304601